Format

Send to

Choose Destination
Osong Public Health Res Perspect. 2017 Oct;8(5):351-357. doi: 10.24171/j.phrp.2017.8.5.09. Epub 2017 Oct 31.

Cost of Tuberculosis Treatment: Evidence from Iran's Health System.

Author information

1
Health Management and Social Development Research Center, Golestan University of Medical Sciences, Gorgan, Iran.
2
Clinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
3
Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran, Iran.
4
School of Public Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Abstract

Objectives:

This study aimed to estimate the cost of smear-positive drug-susceptible pulmonary tuberculosis (TB) treatment of the patients in the Azadshahr district, Golestan Province, Iran.

Methods:

In this retrospective study, all new smear positive pulmonary TB patients who had been registered at the district's health network between April, 2013 and December, 2015 and had successfully completed their treatment were entered into the study (45 patients). Treatment costs were estimated from the provider's perspective using an activity-based costing (ABC) method.

Results:

The cost of treating a new smear-positive pulmonary TB patient was US dollar (USD) 1,409.00 (Iranian Rial, 39,438,260), which can be divided into direct and indirect costs (USD 1,226.00 [87%] and USD 183.00 [13%], respectively). The highest cost (58.1%) was related to care and management of TB patients (including 46.1% human resources costs and 12% directly-observed treatment, short course implementation) and then respectively related to hospitalization (12.1%), supportive activity centers (11.4%), transportation (6.5%), medicines (5.3%), and laboratory tests and radiography (3.2%).

Conclusion:

Using disease-specific cost studies can help the healthcare system management to have correct insight into the financial burden created by the disease. This can subsequently be used in prioritization, planning, operational budgeting, economic evaluation of programs, interventions, and ultimately in disease management.

KEYWORDS:

cost analysis; public health; tuberculosis

Conflict of interest statement

CONFLICTS OF INTEREST No potential conflict of interest relevant to this article was reported.

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center